## How to write great papers and get them accepted in good journals

## From title to references From submission to acceptance




## **Workshop Outline**


#### How to get Published

- Before you begin
- Select your audience
- The article structure
- The review and editorial process
- What not to do... (author ethics)



#### Peer – Reviewed Journal Growth 1665-2001





## **Trends in publishing**

#### Rapid conversion from "print" to "electronic"

- 1997: print only
- 2009: 55% e-only (mostly e-collections) 25% print only 20% print-plus-electronic
- 2013: 95+% electronic access
- Changing role of "journals" due to e-access
- Increased usage of articles
  - at lower cost per article
- Electronic submission
  - Increased manuscript inflow
- New publishing models
  - E.g. "author pays" models (open access), "delayed open access" (open archiving), etc.





## **Open Access Information**



#### **Gold Open Access**



**Gold Open Access** 

- After acceptance, research is made immediately, permanently open access
- Readers can copy and reuse the content as defined by user licenses.
- Costs are covered by a open access publication fee
- Some funding bodies & institutions will reimburse authors for such fees.

#### **Benefits of Gold**

- Immediate open access
- You can choose your user license
- Authors retain copyright
- Share the final published article



### **Tips for publishing Gold Open Access?**



#### **Green Open Access**



**Green Open Access** 

- After publication and acceptance in a subscription journal author publish in a journal
- The article is immediately available to subscribers
- After a delayed period of time (an embargo) authors can post their manuscript to an institutional repository for public use
- Applies to the accepted author manuscript and preprint versions
- Cost of publication are covered and dependent on the subscription model.



### **Complying with new polices**

**V** Three key funder developments:

Research Councils UK

European Commission - Horizon 2020

Every EU country to develop their own policy






Office of Science and Technology Policy (US)



Office of Science and Technology Policy



#### Your personal reason for publishing




 However, editors, reviewers, and the research community don't consider these reasons when assessing your work.



#### Always keep in mind that ...

# .... your published papers, as a permanent record of your research, are your passport to your community !





## Why publish?

**Publishing** is one of the necessary steps **embedded in the** scientific **research process**. It is also necessary for graduation and career progression.

#### What to publish:

- New and original results or methods
- **Reviews or summaries of** particular subject
- Manuscripts that advance the knowledge and understanding in a certain scientific field

What NOT to **publish**:

- Reports of no scientific interest
- Out of date work
- **Duplications** of previously published work
- Incorrect/unacceptable conclusions



## You need a **STRONG** manuscript to present your contributions to the scientific community



#### What is a strong manuscript?

- Has a <u>novel</u>, <u>clear</u>, <u>useful</u>, and <u>exciting</u> message
- Presented and constructed in a <u>logical</u> manner
- Reviewers and editors can grasp the scientific significance <u>easily</u>





## How To Get Your Article Published Before you start



#### **Practical Advice - Information**

- Find out what's Hot
  - http://info.scopus.com/topcited/
  - http://top25.sciencedirect.com/
  - Almetrics Application

#### • Find the trends of the subject area

- Search tips (including alerts)
- Journals, authors, publications per year (Scopus)

#### Evaluate which journal is right for your manuscript

- Impact Factor
- Journal Analyzer (Scopus)
- SNIP & SJR (<u>www.journalmetrics.com</u>)
- *h*-Index

#### Find out more about the journals

- Who are the editors?
- Guide for authors

### IF & SNIP & SJR










#### Use the advanced search options

- Within Google and Google Scholar use the advanced searches and check out the Search Tips.
- In ScienceDirect, Scopus, WoS/WoK and other databases use proximity operators:
  - W/N ← Within (non order specific)
    - pre/n <---- Precedes (order specific)

#### E.g. wind w/3 energy





#### Find out what's Hot (downloads)

ScienceDirect	Top 25 Hottest Articles Medicine and Dentistry January to December 2012 full year	
ww.sciencedirect.com	RSS 1 Blog This!	
select your interest	<ol> <li>The microstructure and surface morphology of radiopaque tricalcium silicate cement exposed to different curing conditions * Article Dental Materials, Volume 28, Issue 5, May 2012, Pages 584-595 Formosa, L.M.; Mallia, B.; Bull, T.; Camilleri, J.</li> <li></li></ol>	
Medicine and Dentistry       [all journals]       browse top 25 archive	<ol> <li>Imperfect information in a quality-competitive hospital market * Article Journal of Health Economics, Volume 29, Issue 4, July 2010, Pages 524-535 Gravelle, H.; Sivey, P.</li> <li>              Cited by SolVerse Scopus (3)      </li> </ol>	
Current January to December 2012 full year   show my alerts	<ol> <li>Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate * Review article Cancer Cell, Volume 21, Issue 3, March 2012, Pages 297-308 Ward, Patrick S.; Thompson, Craig B.</li></ol>	
sign up now! for the e-mail alerts	<ul> <li>4. Childhood obesity: public-health crisis, common sense cure • Review article The Lancet, Volume 360, Issue 9331, August 2002, Pages 473-482 Ebbeling, C.B.; Pawlak, D.B.; Ludwig, D.S.</li></ul>	8
e-mail address 🕖 🕤	<ol> <li>Alzheimer's disease * Review article The Lancet, Volume 377, Issue 9770, March 2011, Pages 1019-1031 Ballard, C.; Gauthier, S.; Corbett, A.; Brayne, C.; Aarsland, D.; Jones, E. Gited by SoïVerse Scopus (193)     </li> </ol>	
Request your free Top 25 certificate	<ol> <li>Cancer Stem Cells: Impact, Heterogeneity, and Uncertainty * Review article Cancer Cell, Volume 21, Issue 3, March 2012, Pages 283-296 Magee, Jeffrey A.; Piskounova, E.; Morrison, Sean J.</li> <li>              Cited by SolVerse Scopus (49)      </li> </ol>	
Tell other people about this service	<ul> <li>Cognitive behaviour therapy for eating disorders: a"transdiagnostic"theory and treatment · Article Behaviour Research and Therapy, Volume 41, Issue 5, May 2003, Pages 509-528 Fairburn, C.G.; Cooper, Z.; Shafran, R.</li> <li>              Cited by SciVerse Scopus (619)      </li> </ul>	
Download the SciVerse ScienceDirect App today!	<ol> <li>Atrial fibrillation * Review article The Lancet, Volume 379, Issue 9816, February 2012, Pages 648-661 Lip, G.Y.; Tse, H.F.; Lane, D.A.</li> <li></li></ol>	
Available for iPhone, iPad, Blackberry and Android devices. >>	<ol> <li>The empirical status of cognitive-behavioral therapy: A review of meta-analyses + Article</li> <li>Clinical Psychology Review, Volume 26, Issue 1, January 2006, Pages 17-31 Butler, A.C.; Chapman, J.E.; Forman, E.M.; Beck, A.T.</li> <li>Cited by SolVerse Socous (471)</li> </ol>	
	10 Costal dataminanta of basilth inoqualities + Artists	-



#### Find out <u>what</u> is being cited and from where

						Scopus Team	
earch   Sources   A	nalytics	Alerts   My list   Settings		Live	e Chat   Help   Tutorials		
Quick Search		Search				Library ca	atalog
our query: TITLE-ABS-KEY				G			
of Edit   🔛 Save   🏷 S		Set feed 26772 Web   570 Patent   197 SelectedSources   Search your library		63			
New accordary documents. [							
		73,289 document results   📶 Analyze results   Show all abstracts				Sort by Cited by	
Search within results		All Download   De Export   Dev citation overview   99 View Cited by   More *		1			
Je	arch	Document title	Author(s)	Date	Source title		Cited
Refine results Limit to Exclud	e	Gene ontology: Tool for the unification of biology View at Publisher   Full Text   G Show abstract   Related documents	Ashburner, M., Ball, C.A., Blake, J.A., Botstein, D., Butler, H., Cherry, J.M., Davis, A.P., (), Sherlock, G.	2000	Nature Genetics 25 (1) , pp. 25-29		759:
Year	8	Protein folding and association: Insights from the interfacial and thermodynamic properties of hydrocarbons	Nicholls, A., Sharp, K.A., Honig, B.	1991	Proteins: Structure, Function and Gene	tics 11 (4) , pp. 281-29	6 485
	1,026) >	View at Publisher   🖵 Show abstract					
	4,398)> 4,523)>	Mold web server for nucleic acid folding and hybridization prediction 3	Zuker, M.	2003	Nucleic Acids Research 31 (13) , pp. 34	406-3415	4536
2009	4,636) >	View at Publisher   Full Text   Related documents					
View more		SCOP: A structural classification of proteins database for the investigation of sequences and structures	Murzin, A.G., Brenner, S.E., Hubbard, T., Chothia, C.	1995	Journal of Molecular Biology 247 (4), p	p. 536-540	4075
Author Name	2	View at Publisher   Full Text   I Show abstract   Related documents					
Dobson, C.M. Fersht, A.R.	(304) > (272) >	Crystal structure of the nucleosome core particle at 2.8 A resolution	Luger, K., Mäder, A.W., Richmond, R.K., Sargent, D.F., Richmond, T.J.	1997	Nature 389 (6648) , pp. 251-260		348
Scheraga, H.A. Uversky, V.N.	(254)>	View at Publisher   Full Text   🗣 Show abstract   Related documents					
Baker, D.	(147)>	Protein structure comparison by alignment of distance matrices	Holm, L., Sander, C.	1993	Journal of Molecular Biology 233 (1), p	p. 123-138	299
View more		View at Publisher   I Show abstract   Related documents					

	*	1.44	19 document results   📶 Analyze results   Show all abstracts			Sort by Cited by	
earch within results			All Download   B> Export   IIII View citation overview   99 View Cited by   More				
	Search	1.4	Document title	Author(s)	Date	Source title	Cited
Refine results	lude	1	GROMACS: Fast, flexible, and free View at Publisher   Full Text   🕞 Show abstract   Related documents	Van Der Spoel, D., Lindahl, E., Hess, B., Groenhof, G., Mark, A.E., Berendsen, H.J.C.	2005	Journal of Computational Chemistry 26 (16) , pp. 1701-1718	2446
Year	*	m	Protein folding. Molecular chaperones in the cytosol: From nascent chain to folded protein	Harti, F.U., Hayer-Harti, M.	2002	Science 295 (5561), pp. 1852-1858	1659
Author Name	*	2	View at Publisher   Full Text   🖵 Show abstract   Related documents		$\square$		
Bukau, B. Buchner, J. Huber, R. Serrano, L.	(83)> (63)> (56)> (53)>	3	Soluble protein oligomers in neurodegeneration: Lessons from the Alzheimer's amyloid β-peptide View at Publisher   Full Text   G Show abstract   Related documents	Haass, C., Selkoe, D.J.	2007	Nature Reviews Molecular Cell Biology 8 (2) , pp. 101-112	1267
Schmid, F.X. View more	(53)>	[] 4	Global, in Vivo, and Site-Specific Phosphorylation Dynamics in Signaling Networks View at Publisher   Full Text   Go Show abstract   Related documents	Olsen, J.V., Blagoev, B., Gnad, F., Macek, B., Kumar, C., Mortensen, P., Mann, M.	2006	Cell 127 (3), pp. 635-648	1246
Subject Area Document Type	*	5	Crystal structure of the ribosome at 5.5 Å resolution View at Publisher   Full Text   G Show abstract   Related documents	Yusupov, M.M., Yusupova, G.Zh., Baucom, A., Lieberman, K., Earnest, T.N., Cate, J.H.D., Noller, H.F.	2001	Science 292 (5518) , pp. 883-896	1225
Source Title Keyword	*	6	SNAREs - Engines for membrane fusion	Jahn, R., Scheller, R.H.	2006	Nature Reviews Molecular Cell Biology 7 (9) , pp. 631-643	803
Affiliation	*		View at Publisher   Full Text   Show abstract   Related documents				
CNRS Centre National de la Recherche Scientifique	(432)>	7	Rapid degradation of a large fraction of newly synthesized proteins by proteasomes View at Publisher   Full Text:   ↓ Show abstract   Related documents	Schubert, U., Antón, L.C., Gibbs, J., Norbury, C.C., Yewdell, J.W., Bennink, J.R.	2000	Nature 404 (6779) , pp. 770-774	708
Max Planck Institute of Biochemistry	(362)> (327)>	8	Hsp70 chaperones: Cellular functions and molecular mechanism View at Publisher   Full Text   I Show abstract   Related documents	Mayer, M.P., Bukau, B.	2005	Cellular and Molecular Life Sciences 62 (6) , pp. 670-684	646
<ul> <li>Technische Universität München</li> <li>Universität Heidelberg</li> </ul>	(282)>	9	Structure of TPR domain-peptide complexes: Critical elements in the assembly of the Hsp70-Hsp90 multichaperone machine View at Publisher   Full Text   GP Show abstract   Related documents	Scheufler, C., Brinker, A., Bourenkov, G., Pegoraro, S., Moroder, L., Bartunik, H., Hartl, F.Ulrich, Moarefi, I.	2000	Cell 101 (2) , pp. 199-210	592



## Find out who is being cited

rticle Figures/Tables (4) References (138)	Thumbnails   Full-Size images	Related Articles		
		<ul> <li>Oxysterol-binding protein-related protein (ORP) 9 is a Cellular Signalling</li> </ul>		
Cancer Call		Quantitative analysis of Akt phosphorylation and activi		
Cell		Biochemical and Biophysical Research Communicatio mTOR and Akt Signaling in Cancer: SGK Cycles In	ns	
olume 12, Issue 1, 10 July 2007, Pages 9-22		Molecular Cell		
		<ul> <li>mTOR and cancer: many loops in one pathway Current Opinion in Cell Biology</li> </ul>		
lo: 10.1016/j.ccr.2007.05.008   How to Cite or Link Using DOI		· Regulation of Akt by arachidonic acid and phosphoinosi		
Permissions & Reprints		Biochimica et Biophysica Acta (BBA) - Molecular and (	Cel	
		View more related articles		
Review				
Defining the Role of mTOR in Cancer		<ul> <li>Show Applications</li> </ul>		
		0% d hu (005)		
)avid A. Guertin <sup>1, 2</sup> , David M. Sabatini <sup>1, 2, 3, 🍐, 🎬</sup>		Cited by (625)		
Whitehead Institute for Biomedical Research and Massachusetts Institute of Technology Department of Biol	ogy 9 Cambridge Center			
Cambridge, MA 02141, USA	ogy, s cambridge center,	<ul> <li>Transforming growth factor-β-induced protein (TGFBI) International Journal of Oncology</li> </ul>	<u></u>	
<sup>2</sup> The Broad Institute, 7 Cambridge Center, Cambridge, MA 02141, USA		• The Hosphoinositide 3-kinase signaling pathway as a t	h	
<sup>3</sup> Center for Cancer Research and Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambri	idge MA 02139 USA	Current Cancer Drug Targets View details of all 625 citing articles in Scopus		
	age, no rez lee, e er l	The first details of an ere stang articles in scopes		
				mealer proprieter mere (pp. y - mereoriar and out.
wailable online 9 July 2007.		Provided b	Soonus	nore related articles
wailable online 9 July 2007.		Provided h	/ Soonus	
wailable online 9 July 2007.		Provided h	<u>Seenus</u>	
wailable online 9 July 2007.		Provided h	•	nore related articles Show Applications
wailable online 9 July 2007.		Provided h	•	nore related articles
wailable online 9 July 2007.			Citer	nore related articles Show Applications d by (625) ors of mTOR overcome drug resistance from topois
wailable online 9 July 2007.	logy Depa	Inhibitors of mTOR overcome drug resistance from topois	Cited • Inhibit Cance	nore related articles Show Applications d by (625) ors of mTOR overcome drug resistance from topois
wailable online 9 July 2007.	logy Depa	■ Inhibitors of mTOR overcome drug	Cited Inhibit Cance Trans Intern	nore related articles Show Applications d by (625) ors of mTOR overcome drug resistance from topois r Letters forming growth factor-β-induced protein (TGFBI) s tetional Journal of Oncology
wailable online 9 July 2007.	logy Depa	Inhibitors of mTOR overcome drug resistance from topois Cancer Letters, Volume 311, Issue 1, 1 December 2011,	Cited Inhibit Cance Trans Intern The p	nore related articles Show Applications d by (625) ors of mTOR overcome drug resistance from topois forming growth factor-β-induced protein (TGFBI) s
wailable online 9 July 2007.	logy Depa nusetts Ar	Inhibitors of mTOR overcome drug     resistance from topois Cancer Letters, Volume 311, Issue 1, 1 December 2011,     Pages 20-28     Abstract     The present study was performed to investigate the	Cited Inhibit Cance Trans Intern The p Curre	nore related articles  Show Applications  d by (625)  ors of mTOR overcome drug resistance from topois er Letters forming growth factor-β-induced protein (TGFBI) s terional Journal of Oncology hosphoinostide 3-kinase signaling pathway as a th
wailable online 9 July 2007.		■ Inhibitors of mTOR overcome drug resistance from topois Cancer Letters, Volume 311, Issue 1, 1 December 2011, Pages 20-28 Abstract The present study was performed to investigate the possible role of mTOR inhibitors in restoring chemosensitivity to adriamycin/cisplatin and elucidate	Cited Inhibit Cance Trans Intern The p Curre	nore related articles Show Applications d by (625) ors of mTOR overcome drug resistance from topols er Letters forming growth factor-β-induced protein (TGFBI) s ational Journal of Oncology hosphoinsatile 2-kinase signaling pathway as a th int Cancer Drug Targets
wailable online 9 July 2007.		Inhibitors of mTOR overcome drug resistance from topois Cancer Letters, Volume 311, Issue 1, 1 December 2011, Pages 20-28 Abstract The present study was performed to investigate the possible role of mTOR inhibitors in restoring chemosensitivity to adriamycin/cisplatin and elucidate the underlying mechanism. Combining	Cited Inhibit Cance Trans Intern The p Curre	nore related articles Show Applications d by (625) ors of mTOR overcome drug resistance from topois er Letters forming growth factor-β-induced protein (TGFBI) s intional Journal of Oncology hosphoinositide 3-kinase signaling pathway as a th mt Cancer Drug Targets details of all 625 citing articles in Scopus
wailable online 9 July 2007.		■ Inhibitors of mTOR overcome drug resistance from topois Cancer Letters, Volume 311, Issue 1, 1 December 2011, Pages 20-28 Abstract The present study was performed to investigate the possible role of mTOR inhibitors in restoring chemosensitivity to adriamycin/cisplatin and elucidate	Cited Inhibit Cance Trans Intern The p Currer View	nore related articles Show Applications d by (625) ors of mTOR overcome drug resistance from topols er Letters forming growth factor-β-induced protein (TGFBI) s tetional Journal of Oncology hosphoinosidid 2-kinase signaling pathway as a th int Cancer Drug Targets details of all 625 otting articles in Scopus Periodeen her Sco
wailable online 9 July 2007.	nusetts Ar	Inhibitors of mTOR overcome drug resistance from topois Cancer Letters, Volume 311, Issue 1, 1 December 2011, Pages 20-28 Abstract The present study was performed to investigate the possible role of mTOR inhibitors in restoring chemosensitivity to adriamycin/cisplatin and elucidate the underlying mechanism. Combing adriamycin/cisplatin with torisel synergistically inhibited	Cited • Inhibit Cenc. • Trans Intern • The p Curre • View Relat	nore related articles Show Applications d by (625) ors of mTOR overcome drug resistance from topois er Letters forming growth factor-β-induced protein (TGFBI) s intional Journal of Oncology hosphoinositide 3-kinase signaling pathway as a th mt Cancer Drug Targets details of all 625 citing articles in Scopus

## Find out <u>who</u> is being cited

			200	MALL HINGS
🔶 🍄 🔘 Scopus - Search Result:			<u>ه</u> -	🔊 👘 🔹 🔂 Page 🔹 🎯 Too
SciVerse Scopus	Hub   ScienceDirect   Scopus   SciTopics   Applications	4	Anthony Newman is log	ged in   Logout   Go to SciVal Su Brought to you by The Scopus Team
Search   Sources   Analy	cs + My alerts + My list + My settings			Live Chat   He
Quick Search	Search			Library catalogu
Scopus: 97 More	Web Patents SelectedSources	alert   💦 Set feed   🐉 View search h	listory	
(	Document results: 97   Show all abstracts		Go	to page: 1 of 5 Go   Next ≈
Search within results	All       With selected:         Download PDF   December 2000       Export   Print   Market 2000         Page       View citations   With vertices   Kapace		view	Sort by Date (Newest)
Refine results	Document title	Author(s)	Date Source title	Citation
Limit to Exclude Year	MTOR complex 1 regulates lipin 1 localization to control the srebp pathway	Peterson, T.R., Sengupta, S.S., Harris, T.E., Carmack, A.E., Kang S.A., Balderas, E., Guertin, D.A., ( Sabatini, D.M.		), pp. 408-420 0
2011 (10)	View at publisher   Full Text   📮 Show abstract   🔍 Related docu	ments		
2010     (12)     2009     (13)     2008     (5)	2 The TASCC of secretion	Zoncu, R., Sabatini, D.M.	2011 Science 33	2 (6032), pp. 923-925 0
2007 (5)				
View more   View fewer Author Name	<ul> <li>mTORC1 activates SREBP-1c and uncouples lipogenesis from gluconeogenesis</li> <li>(Proceedings of the National Academy of Sciences of the United States of Amer (2010) 107, 8, (3281-3282) DOI: 10.1073/pnas.1000323107)</li> </ul>			is of the <u>National</u> f <u>Sciences of the</u> <u>mited</u> <u>merica</u> 107 (16), pp.



## Find out <u>who</u> is being cited – in more depth

😫 🏟 Scopus - Citation overview										🟠 • 🖾 - 🖶 • 🗗 Page • 🎯 1	iools •
Search   Sources   Analytics   My alerts   My list	I My se	ettings								Live Chat	Help
Quick Search Search										Library catalo	gue
Citation overview			Cit	ation	s rec	eived	since	9 1996			
This is a citation overview for a set of 97 documents.										🗈 Export   📃 Print	
Overview options			Hi	de 🖃							
Exclude from citation overview:       Self citations of all authors         Sort documents       Date range         Year descending       2009         Year descending       2009		odate ov	verview							<i>h</i> -Graph ≪ Back This is a /> graph for a set of 97 documents. The /> graph measures the impact of a set of arti // index = 57 (of the 97 documents considered for the />>	cles and shows the number of citations per document.
					Citatio	ons			h index = 57 ⊡		ormation for articles published before 1996. About h-Graph Line Chart   Table
97 Cited Documents 🔛 Save list		<2009	2009	2010	2011	Subtotal	>2011	Total	Document <i>h</i> index	1500 -	/
F X Delete	Total	6714	2280	2823	2463	7566	5	14285	View h-Graph Of the 97 documents considered	1400 - 1300 -	
1 🔲 2011 Functional genomics reveal that					3	3		3	for the h index, 57 have been cited at least 57 times.	1200	
2 🔲 2011 MTOR complex 1 regulates lipin 1						0		0	Scopus does not have complete	2 1000 - 3 900 -	
3 🔲 2011 A haploid genetic screen identif					1	1		1	citation information for articles published before 1996.	9 000 -	
4 🔲 2011 The mTOR-regulated phosphoproteo					2	2		2	About h-Graph	00 700	
5 🔲 2011 A radical role for TOR in longev					1	1		1		400	
										200 100 0 160 320 480 640 800	960 1120 1280 1440



Document

#### Questions to answer before you write

#### Think about **WHY you want to publish your work**.

- Is it new and interesting?
- Is it a current hot topic?
- Have you provided solutions to some difficult problems?
- Are you **ready** to publish at this point?

#### If <u>all</u> answers are "<u>yes</u>", then start preparations for your manuscript





## What type of manuscript?

- Full articles/Original articles;
- Letters/Rapid Communications/Short communications;
- Review papers/perspectives;

Self-evaluate your work: Is it sufficient for a full article? Or are your results so thrilling that they need to be shown as soon as possible?

Ask your supervisor and colleagues for advice on manuscript type. Sometimes outsiders see things more clearly than you.



#### Select the best journal for submission

- Look at your references these will help you narrow your choices.
- Review recent publications in each candidate journal. Find out the hot topics, the accepted types of articles, etc.
- Ask yourself the following questions:
  - Is the journal peer-reviewed to the right level?
  - Who is this journal's audience?
  - How fast does it make a <u>decision</u> or <u>publish</u> your paper?
  - What is the journal's Impact Factor?
  - Does it really exist or is **dubious**? (check for example Beall's List of Predatory Open Access Publishers)
- DO NOT gamble by submitting your manuscript to more than one journal at a time.
  - International ethics standards prohibit multiple/simultaneous submissions, and editors DO find out! (Trust us, they DO!)



#### **Choose the right journal**



al information

ucts

emical <u>na</u>cology

ription nation

al-related nation

ort & contact

t Elsevier

t your view

Breaking Boundaries.

#### **BIOCHEMICAL PHARMACOLOGY**

Editor-in-Chief: **5.J. Enna** See editorial board for all editors information

Sign up for the Pharmacology Newsletters Sign up here!

**BCP Special Issues: Published and Future issues** 

Danuary 2008 Addictions Special Issue Edited by David Weinshenker

#### Description

Biochemical Pharmacology is an international journal devoted to publishing original work on the interaction of drugs and nontherapeutic xenobiotics with biological systems. While particular emphasis is placed on reporting findings that relate to the actions and metabolism of drugs and toxic substances at the biochemical and molecular levels, submissions in the areas of behavioral and physiological pharmacology and toxicology are also encouraged if they describe studies directed at defining mechanisms of action. All areas of the field are represented in the journal including, but not limited to, cancer chemotherapy, neuropharmacology, inflammation/immunopharmacology, antimicrobials, behavioral, respiratory, gastrointestinal, cardiovascular, and endocrine pharmacology and toxicology. Submissions relating to either pharmacodynamics or pharmacokinetics are considered. Reports based on experiments conducted with mixtures, plant or animal extracts will not be considered for publication unless the chemical structures and concentrations of all substances are known. Submissions to the journal must be in English.

The journal publishes the following types of reports:

(1) Full-length Research Papers. These contain the results of original research on an issue of relevance to the field of pharmacology.

(2) Commentaries. These are commissioned articles that provide the author's view on a selected topic of



 Investigate all candidate journals to find out

- Aims and scope
- Accepted types of articles
- Readership
- Current hot topics
  - go through the abstracts of recent publications)



#### What is the Impact Factor (IF)?

#### **Impact Factor**


[the average annual number of citations per article published]

- For example, the 2011 impact factor for a journal is calculated as follows:
  - A = the number of times articles published in 2009 and 2010 were cited in indexed journals during 2011
  - B = the number of "citable items" (usually articles, reviews, proceedings or notes; not editorials and letters-to-the-Editor) published in 2009 and 2010
  - 2011 impact factor = A/B
  - e.g. <u>600 citations</u> = 2.000
     150 + 150 articles






#### **Influences on Impact Factors: Subject Area**







So you now have a sequence list of candidate journals for your manuscript?

## Write your draft as if you are going to submit to the first on your list. Use its Guide to Authors



#### Read the 'Guide to Authors'- Again and again!

- Stick to the Guide for Authors in your manuscript, even in the first draft (text layout, nomenclature, figures & tables, references etc.). In the end it will save you time, and also the editor's.
- Editors (and reviewers) do not like wasting time on poorly prepared manuscripts. It is a sign of disrespect.





#### Read the 'Guide to Authors'- Again and again!



#### Guide for authors

Submit your paper

#### Track your paper

Order journal

View articles

Abstracting and indexing

Editorial board

#### Browse journals > Journal of Molecular Biology > Guide for authors

#### **Guide for Authors**

#### Author information pack

- INTRODUCTION
- Editorial policy
- · Sharing of reagents and data
- Sequence data
- Structural data
- NMR assignments
- Cell lines
- Types of paper
- Contact details for submission
- BEFORE YOU BEGIN
- Ethics in publishing
- Conflict of interest
  - Submission declaration
  - Changes to authorship
  - Copyright
     Retained author rights
  - Funding body agreements and policies

- Open access
- Language (usage and editing services)
- Submission
- PREPARATION
- Use of wordprocessing software
- Article structure
- Subdivision
- Essential title page information
- Abstract
- Graphical abstract
- Highlights
- Keywords
- Abbreviations
- Introduction
- Results
- Discussion
- Materials and methods

- Database linking
- Accession numbers
- Glossary
- Acknowledgements
- Footnotes
- Artwork
- Color artwork
- Tables
- References
- · Journal abbreviations source
- Supplemental data
- Additional information
- AFTER ACCEPTANCE
- Use of the Digital Object
  Identifier
- Proofs
- Offprints
- AUTHOR INQUIRIES





32

#### An international editor says...

#### "The following problems appear much too frequently"

- Submission of papers which are clearly out of scope
- Failure to format the paper according to the Guide for Authors
- Inappropriate (or no) suggested reviewers
- Inadequate response to reviewers
- Inadequate standard of English
- Resubmission of rejected manuscripts without revision

#### - Paul Haddad, Editor, Journal of Chromatography A



#### **Scientific Language – Overview**

#### Write with clarity, objectivity, accuracy, and brevity.

- Key to successful scientific writing is to be alert for common errors:
  - Sentence construction
  - Incorrect tenses
  - Inaccurate grammar
  - Not using English

Check the <u>Guide for Authors</u> of the target journal for language specifications



#### Scientific Language – Sentences

- Write direct and <u>short</u> sentences
- <u>One idea</u> or piece of information <u>per</u> <u>sentence</u> is sufficient
- <u>Avoid</u> multiple statements in one sentence

#### An example of what <u>NOT</u> to do:

"If it is the case, intravenous administration should result in that emulsion has higher intravenous administration retention concentration, but which is not in accordance with the result, and therefore the more rational interpretation should be that SLN with mean diameter of 46nm is greatly different from emulsion with mean diameter of 65 nm in entering tumor, namely, it is probably difficult for emulsion to enter and exit from tumor blood vessel as freely as SLN, which may be caused by the fact that the tumor blood vessel aperture is smaller."



### Authorship

- Policies regarding authorship can vary
- One example: the International Committee of Medical Journal Editors ("Vancouver Group") declared that an author must:
  - 1. **substantially contribute** to conception and design, or acquisition of data, or analysis and interpretation of data;
  - 2. draft the article or revise it critically for important intellectual content; and
  - **3.** give their approval of the final full version to be published.
  - 4. <u>ALL three</u> conditions must be fulfilled to be an author!

All others would qualify as "Acknowledged Individuals"



### **Authorship - Order & Abuses**

- General principles for who is listed first
  - First Author
    - Conducts and/or supervises the data generation and analysis and the proper presentation and interpretation of the results
    - Puts paper together and submits the paper to journal
  - Corresponding author
    - The first author or a senior author from the institution
      - Particularly when the first author is a PhD student or postdoc, and may move to another institution soon.
- Abuses to be avoided
  - <u>Ghost Authorship</u>: leaving out authors who should be included
  - <u>Gift Authorship</u>: including authors who did not contribute significantly



### **Author names: common problems**

### Different Spellings

- Järvinen / Jaervinen / Jarvinen
- Lueßen / Lueben / Luessen
- van Harten / Vanharten / Van
- First/Last Names
  - Asian names often difficult for Europeans or Americans
- What in case of marriage/divorce?

### **Be consistent!**

If you are not, how can others be?



### Author Profiles...be consistent if you can, or correct

	Search		
🛿 Print   💟 E-mail   🕼 Request author detail c	corrections		
Van'T Veer, Laura J.			
Personal			
Name	Van'T Veer, Laura J.		
Other formats	van't Veer, Laura J. Van't Veer, L. J. Van 't Veer, L. J. van't Veer, L. J. Van't Veer, L. J. Van't Veer, L. J. van't Veer, Laura Van't Veer, Laura Van 't Veer, L. Van't Veer, L. Van't Veer, L. Van't Veer, L.	Van 't Veer, Laura J. Van 'T Veer, L. J. van 't Veer, L. J. van 't Veer, Laura Van 't Veer, Laura van 't Veer, Laura van 't Veer, L. Van 't Veer, Laura Van 'T Veer, Laura Van 'T Veer, Laura J.	
Author ID	7004922326		
Affiliation	The Netherlands Cancer Institute, Amsterdam Netherlands		
Research			
Documents	204 🛛 🔮 View Author Evaluator   🕂 Add to my list   🔖 Set alert   🔝 S	204 🛛 🔮 View Author Evaluator   🕂 Add to my list   🔖 Set alert   🔝 Set feed	
References	4242		
Citations	18676 total citations by 12720 documents 📶 View citation overview   🐤	18676 total citations by 12720 documents 📶 View citation overview   下 Set alert	
ndex	54 🛛 🛛 View h-Graph The h Index co	nsiders Scopus articles published after 1995.	
Co-authors	150 (maximum 150 co-authors can be displayed)		
Web search	8304		
Subject area	Medicine Biochemistry, Genetics and Molecular Biology Agricultural and Biological Sciences More		

### **ORCID: Author Profile 2.0**

# ORCID

Connecting Research and Researchers

• Open

D

- Researcher &
- Contributor

### The Challenge:

- The scholarly record is broken
- Name ambiguity is an issue

### The Solution:

• Establish a researcher identifier registry (partnership between Univs, Publishers, funding bodies...)!

### The Benefits:

- Current authors can claim already published work
- New authors can establish unique identifier

#### ORCID Launches Registry October 16, 2012


ORCID (Open Researcher and Contributor ID) is excited to announce the launch of its Registry (http://orcid.org), where researchers can distinguish themselves by creating a unique personal identifier.

"ORCID addresses a problem shared by individuals and organizations across the research community: reliably connecting Launchegarch 6th 9.640, 0.00 for 20th Ecutive Director of...

Read more >




### **General Structure of a Research Article**





### The process of writing – building the article





### Title

 A good title should contain the fewest possible words that adequately describe the contents of a paper.

#### Effective titles

- Identify the main issue of the paper
- Begin with the subject of the paper
- Are accurate, unambiguous, specific, and complete
- Are as short as possible
- Articles with short, catchy titles are often better cited
- Do not contain rarely-used abbreviations
- Attract readers Remember: readers are the potential authors who will cite your article





In an "electronic world, keywords determine whether your article is found or not!


Avoid making them

- too general ("drug delivery", "mouse", "disease", etc.)
- too narrow (so that nobody will ever search for it)

Effective approach:

Look at the keywords of articles relevant to your manuscript Play with these keywords, and see whether they return relevant papers, neither too many nor too few





### Abstract

### Tell readers what you did and the important findings


- One paragraph (between 50-250 words) often, plus Highlight bullet points
- Advertisement for your article
- A clear abstract will strongly influence if your work is considered further

Graphite intercalation compounds (GICs) of composition CxN(SO2CF3)2 · δF are prepared under ambient conditions in 48% hydrofluoric acid, using K2MnF6 as an oxidizing reagent. The stage 2 GIC product structures are determined using powder XRD and modeled by fitting one dimensional electron density profiles. A new digestion method followed by selective fluoride electrode elemental analyses allows the determination of free fluoride within products, and the compositional x and δ parameters are determined for reaction times from 0.25 500 h. What are the main findings

# The place to convince readers that you know why your work is relevant, also for them

#### Answer a series of questions:

- What is the problem?
- Are there any existing solutions?
- Which one is the best?
- What is its main limitation?
- What do you hope to achieve?



46

### Pay attention to the following

- Before you present your new data, put them into perspective first
- Be brief, it is <u>not</u> a history lesson
- Do not mix introduction, results, discussion and conclusions. Keep them separate
- Do not overuse expressions such as "novel", "first time", "first ever", "paradigm shift", etc.

#### Cite only relevant references

 Otherwise the editor and the reviewer may think you don't have a clue where you are writing about



7

### **Methods / Experimental**


- Include all important details so that the reader can repeat the work.
  - Details that were previously published can be omitted but a general summary of those experiments should be included
- Give vendor names (and addresses) of equipment etc. used
- All chemicals must be identified
  - Do not use proprietary, unidentifiable compounds without description
- Present proper control experiments
- Avoid adding comments and discussion.
- Write in the past tense
  - Most journals prefer the passive voice, some the active.
- Consider use of Supplementary Materials
  - Documents, spreadsheets, audio, video, .....

*Reviewers will criticize incomplete or incorrect descriptions, and may even recommend rejection* 



### **Results – what have you found?**

- The following should be included
  - the main findings
    - Thus not all findings



- Findings from experiments described in the Methods section
- Highlight findings that differ from findings in previous publications, and unexpected findings
- Results of the statistical analysis




### **Results – Figures and tables**

### Illustrations are critical, because


- Figures and tables are the most efficient way to present results
- Results are the driving force of the publication
- Captions and legends must be detailed enough to make figures and tables self-explanatory
- No duplication of results described in text or other illustrations


"One Picture is Worth a Thousand Words" Sue Hanauer (1968)




### **Results – Appearance counts!**


- Un-crowded plots
  - 3 or 4 data sets per figure; well-selected scales; appropriate axis label size; symbols clear to read; data sets easily distinguishable.
- Each photograph must have a scale marker of professional quality in a corner.
- Text in photos / figures in English
  - > Not in French, German, Chinese, Korean, ...
- Use color ONLY when necessary.
  - If different line styles can clarify the meaning, then never use colors or other thrilling effects.
- Color must be visible and distinguishable when printed in black & white.





• Do not include long boring tables!







### **Discussion** – what do the results mean?

- It is the most important section of your article. Here you get the chance to SELL your data!
  - Many manuscripts are <u>rejected</u> because the Discussion is weak
- Check for the following:
  - How do your results relate to the original question or objectives outlined in the Introduction section?
  - Do you provide interpretation for each of your results presented?
  - Are your results consistent with what other investigators have reported? Or are there any differences? Why?
  - Are there any limitations?
  - Does the discussion logically lead to your conclusion?
- Do not
  - Make statements that go beyond what the results can support
  - Suddenly introduce new terms or ideas



### Conclusions

- Present global and specific conclusions
- Indicate uses and extensions if appropriate
- Suggest future experiments and indicate whether they are underway
- Do not summarize the paper
  - The abstract is for that purpose
- Avoid judgments about impact



### **References: get them right!**


- Please adhere to the Guide for Authors of the journal
- It is <u>your</u> responsibility, not of the Editor's, to format references correctly!
- Check
  - Referencing style of the journal
  - The spelling of author names, the year of publication
  - Punctuation use
  - Use of "et al.": "et al." translates to "and others",
- Avoid citing the following if possible:
  - Personal communications, unpublished observations, manuscripts not yet accepted for publication
    - Editors may ask for such documents for evaluation of the manuscripts
  - Articles published only in the local language, which are difficult for international readers to find



### **Supplementary Material**

- Data of secondary importance for the main scientific thrust of the article
  - e.g. individual curves, when a representative curve or a mean curve is given in the article itself
- Or data that do not fit into the main body of the article
  - e.g. audio, video, ....
- Not part of the printed article
  - Will be available online with the published paper
- Must relate to, and support, the article





### **Suggest potential reviewers**

- Your suggestions will help the Editor to move your manuscript to the review stage more efficiently.
- You can easily find potential reviewers and their contact details from articles in your specific subject area (e.g., your references).
- The reviewers should represent at least two regions of the world. And they should not be your supervisor or close friends.
- Be prepared to suggest 3-6 potential reviewers, based on the Guide to Authors.






### Do everything to make your submission a success

- No one gets it right the first time!
  - Write, and re-write ....
- Suggestions
  - After writing a first version, take several days of rest.
     Come back with a critical, fresh view.
  - Ask colleagues and supervisor to review your manuscript. Ask them to be highly critical, and *be open to their suggestions*.
  - Make changes to incorporate comments and suggestions. Get all co-authors to approve version to submit.

Then it is the point in time to submit your article!




### **The Peer Review Process – not a black hole!**



Many journals use a system of initial editorial review. Editors may reject a manuscript without sending it for review

### Why?

- The peer-review system is grossly overloaded and editors wish to use reviewers only for those papers with a good probability of acceptance.
- It is a disservice to ask reviewers to spend time on work that has clear and evident deficiencies.






### First Decision: "Accepted" or "Rejected"

### Accepted

• Very rare, but it happens



#### Congratulations!

- Cake for the department
- Now wait for page proofs and then for your article to be online and in print

### Rejected


- Probability 40-90% ...
- Do not despair
  - It happens to everybody

#### Try to understand WHY

- Consider reviewers' advice
- Be self-critical
- If you submit to another journal, begin as if it were a new manuscript
  - Take advantage of the reviewers' comments
  - They may review your manuscript for the other journal too!
  - Read the Guide for Authors of the new journal, again and again.



### **The Peer Review Process – revisions**



### First Decision: "Major" or "Minor" Revision

### Major revision

- The manuscript may finally be published in the journal
- Significant deficiencies must be corrected before acceptance
- Usually involves (significant) textual modifications and/or additional experiments

### Minor revision

- Basically, the manuscript is worth being published
- Some elements in the manuscript must be clarified, restructured, shortened (often) or expanded (rarely)
- Textual adaptations
- "Minor revision" does NOT guarantee acceptance after revision!



### **Manuscript Revision**

### Prepare a detailed Response Letter

- Copy-paste <u>each</u> reviewer comment, and type your response below it
- State specifically which changes you have made to the manuscript
  - Include page/line numbers
  - No general statements like "Comment accepted, and Discussion changed accordingly."
- Provide a *scientific* response to comments to accept, .....
- ..... or a convincing, solid and <u>polite</u> rebuttal when you feel the reviewer was wrong.
- Write in such a manner, that your response can be forwarded to the reviewer without prior editing

Do not do yourself a disfavour, but cherish your work

- You spent weeks and months in the lab or the library to do the research
- It took you weeks to write the manuscript......



.....Why then run the risk of avoidable rejection by not taking manuscript revision seriously?



## Increasing the likelihood of acceptance

### All these various steps are not difficult

You have to be consistent.

You have to check and recheck before submitting.

Make sure you tell a logical, clear, story about your findings.

Especially, take note of referees' comments. They improve your paper.

This should increase the likelihood of your paper being accepted, and being in the 30% (accepted) not the 70% (rejected) group!



### What leads to acceptance ?

- <u>Attention to details</u>
- <u>C</u>heck and double check your work
- <u>C</u>onsider the reviewers' comments
- <u>English must be as good as possible</u>
- <u>P</u>resentation is important
- <u>Take your time with revision</u>
- Acknowledge those who have helped you
- <u>N</u>ew, original and previously unpublished
- <u>C</u>ritically evaluate your own manuscript
- <u>E</u>thical rules must be obeyed

– Nigel John Cook Editor-in-Chief, *Ore Geology Reviews* 



### What NOT to do (Publishing Ethics)

# Author's responsibilities



## **Ethics Issues in Publishing**

### **Scientific misconduct**

Falsification of results

### **Publication misconduct**

- Plagiarism
  - Different forms / severities
  - The paper must be original to the authors
- Duplicate publication
- Duplicate submission
- Appropriate acknowledgement of prior research and researchers
- Appropriate identification of all co-authors
- Conflict of interest



### Plagiarism

- A short-cut to long-term consequences!
- Plagiarism is considered a serious offense by your institute, by journal editors, and by the scientific community.
- Plagiarism may result in *academic charges*, but will certainly cause rejection of your paper.
- Plagiarism will *hurt your reputation* in the scientific community.
   No Copying



### **Duplicate Publication**

- Two or more papers, without full cross reference, share the same hypotheses, data, discussion points, or conclusions
- An author should not submit for consideration in another journal a previously published paper.
  - Published studies <u>do not need to be repeated</u> unless further confirmation is required.
  - Previous publication of an abstract during the proceedings of conferences does not preclude subsequent submission for publication, but <u>full disclosure</u> should be made at the time of submission.
  - Re-publication of a paper in another language is acceptable, provided that there is <u>full and prominent disclosure of its original source</u> at the time of submission.
  - At the time of submission, authors should disclose details of related papers, even if in a different language, and similar papers in press.
  - This includes translations



### **Plagiarism Detection Tools**

- Elsevier is participating in 2 plagiarism detection schemes:
  - TurnItIn (aimed at universities)
  - IThenticate (aimed at publishers and corporations)

Manuscripts are checked against a database of 20 million peer reviewed articles which have been donated by 50+ publishers, including Elsevier.

All post-1994 Elsevier journal content is now included, and the pre-1995 is being steadily added week-by-week


- Editors and reviewers
- Your colleagues
- "Other" whistleblowers
  - "The walls have ears", it seems ...







### **Publication ethics – Self-plagiarism**



72



#### doi:10.1016/j.sigpro.2005.07.019 🕜 Cite or Link Using DOI Copyright © 2005 Elsevier B.V. All rights reserved.



Available online 24 August 2005.

This article has been retracted at the request of the Editor-in-Chief and P http://www.elsevier.com/locate/withdrawalpolicy.

Reason: This article is virtually identical to the previously published article algorithm for SNR improvement in ultrasonic NDT", Independent Nonde International, volume 38 (2005) 453 - 458 authored by M. Ruiz Report.

the echoes issuing from the flaws to be detected. Therefore, it cannot be cancelled by classical time averaging or matched band-pass filtering techniques.

Many signal processing techniques have been utilized for signal-to-noise ratio (SNR) improvement in ultrasonic NDT of highly scattering materials. The most popular one is the split spectrum processing (SSP) [1-3], because it makes possible real-time ultrasonic test for industrial applications, providing quite good results. Alternatively to SSP, wavelet transform (WT) based denoising/detection methods have been proposed during recent years [4-8], yielding usually to higher improvements of SNR at the expense of an increase in complexity. Adaptive time-frequency analysis by basis pursuit (BP) [9,10] is a secent technique for decomposing a signal into an optimal superposition of elements in an overcomplete waveform dictionary. This technique and some other related techniques have been successfully applied to denoising ultrasonic signals co taminated with grain noise in highly scattering materials [11,12], as an alternative to the W technique, the computational cost of e BP algorithm being the main drawback

In this paper, we propose a del mo him pursuit-based signal processing mean of our im-proving SNR in ultrascel. NDT C highly scattering materials, such a start and composites. Matching pusuit is used instead of BP to reduce the complexity. Device its itema nature, the method is fast exactly to be real-time implemen-ted. The performance of the proposed method has been evaluated us noth or puter simulation and experimental reads, then when the input SNR (NRin) is lower own 0dB (the level of erostructures is above the echoe. catte level of charge.

#### 2. Matching pursuit

Matching pursuit was introduced by Mallat and Zhang [13]. Let us suppose an approximation of the ultrasonic backscattered signals x[n] as a linear expansion in terms of functions  $g_i[n]$  chosen from an over-complete dictionary. Let H be a Hilbert

space. We define the over-complete dictionary as a family  $D = \{a; i = 0, 1, \dots, L\}$  of vectors in H. such as  $||g_i|| = 1$ .

The problem of choosing functions  $g_i[n]$  that best approximate the analysed signal x[n] is computationally very complex. Matching pursuit is an iterative algorithm that offers sub-optimal solutions for decomposing sizes the terms of expansion functions chosen from a dominary, where I' norm is used as the approximation metric because of its mathemy cal convisience. When a well-designed dictionary is und in sing pursuit, the non-linear nature of the algorithm leads to compact at rave such model

In each gas of the introduce procedure, vector  $g_i[n]$  which give the largest oner product with the analysed signal is osen. The contribution of this vertices then subtracted from the signal and the cess is repeated on the residual. At the mth ration the sidue is



where  $\alpha_{imi}$  is the weight associated to optimum atom  $g_{int}[n]$  at the with iteration.

( ×[r

The weight  $a_i^{\mu}$  associated to each atom  $g_i[n] \in D$ at the wth iteration is introduced to compute all the inner products with the residual  $r^{\mu}[w]$ :

$$i_{i}^{\mu} = \frac{(r^{\mu}[a], g_{i}[a])}{(g_{i}[a], g_{i}[a])} = \frac{(r^{\mu}[a], g_{i}[a])}{\|g_{i}[a]\|^{2}}$$
  
=  $k^{\mu}[a], g_{i}[a]), \qquad (2)$ 

The optimum atom  $g_{(be)}[n]$  (and its weight  $\alpha_{(be)}$ ) at the with iteration are obtained as follows:

$$g_{\ell m}[n] = \arg \min_{q \in D} \|p^{m+1}[n]\|^2$$
  
=  $\arg \max_{a \in Q} \|a_i^m\|^2 = \arg \max_{a \in Q} \|a_i^m\|.$  (3)

The computation of correlations  $(r^{\mu}[n], q, [n])$  for all vectors q[n] at each iteration implies a high computational effort, which can be substantially reduced using an updating procedure derived from Eq. (1). The correlation updating procedure [13] is performed as follows:

 $(r^{m+1}[n], g_i[n]) = (r^m[n], g_i[n])$ 

 $-\alpha_{ijij} \langle g_{fmi}[n], g_i[n] \rangle$ .

An article in which the authors committed plagiarism: it will not be removed from ScienceDirect ever. Everybody who downloads it will see the reason for the retraction...


Signal Processing Volume 86, Issue 5, May 2006, Pages 962-970

#### ELSEVIER

(4)

### Figure Manipulation – <u>some</u> things are allowed

As long as they don't obscure or eliminate info present in the original image




Must be disclosed in the figure legend Enhanced Obscured Moved Removed Introduced





### **Figure Manipulation Example - Different authors and reported experiments**

#### Am J Pathol, 2001

















Worked on, added to, becomes:


Rotated 180°























Life Sci, 2004






















### **References and Acknowledgements**

- Guide for Authors of Elsevier journals.
- http://owl.english.purdue.edu/owl/
- http://www.physics.ohio-state.edu/~wilkins/writing/index.html
- Petey Young. Writing and Presenting in English. The Rosetta Stone of Science. Elsevier 2006
- EDANZ Editing training materials. 2006
- Jullian Eastoe. Co-editor, Journal of Colloid and Interface Science
- Peter Thrower. Editor-in-chief, Carbon
- Roel Prins. Editor-in-chief, Journal of Catalysis
- Nigel Cook. Editor-in-chief, Ore Geology Reviews.
- Frans P. Nijkamp, Journal of Ethnopharmacology
- Wilfred CG Peh. Editor, Singapore Medical Journal
- Malcolm W. Kennedy. Professor, Institue of Biomedical and Life Sciences, University of Glasgow, UK



### **Further reading for you**

- Mark Ware Consulting Ltd, Publising and E-learning Consultancy. Scientific publishing in transition: an overview of current developments. Sept., 2006. <u>www.stm-assoc.org/storage/Scientific\_Publishing\_in\_Transition\_White\_Paper.pdf</u>
- Ethical Guildlines for Journal Publishing, Elsevier. http://www.elsevier.com/wps/find/intro.cws\_home/ethical\_guidelines#Duties%20of%20Authors
- International Committee of Medical Journal Editors. Uniform Requirements for Manuscripts Submitted to Biomedical Journals: Writing and Editing for Biomedical Publication. Feb. 2006
- http://www.publicationethics.org.uk/guidelines
- http://www.icmje.org/index.html#ethic
- <u>http://www.onlineethics.org/</u>
- http://owl.english.purdue.edu/owl/
- http://www.physics.ohio-state.edu/~wilkins/writing/index.html
- George D. Gopen, Judith A. Swan. The science of Scientific Writing. American Scientist (Nov-Dec 1990), Vol. 78, 550-558.
- Michael Derntl. Basics of Research Paper Writing and Publishing. <u>http://www.pri.univie.ac.at/~derntl/papers/meth-se.pdf</u>
- Thomas H Adair. Professor, Physiology & Biophysics Center of Excellence in Cardiovascular-Renal Research, University of Mississippi Medical Center. <u>http://dor.umc.edu/ARCHIVES/WritingandpublishingaresearcharticleAdair.ppt</u>
- Bruce Railsback. Professor, Department of Geology, University of Georgia. Some Comments on Ethical issues about research. www.gly.uga.edu/railsback/11111misc/ResearchEthics.html
- Peter Young. Writing and Presenting in English. The Rosetta Stone of Science. Elsevier 2006.
- Philip Campbell. Editor-in-Chief, Nature. Futures of scientific communication and outreach. June 2007.
- http://scholarlyoa.com/2012/12/06/bealls-list-of-predatory-publishers-2013/
- http://www.youtube.com/watch?v=kges3mN5rDk&feature=youtube\_gdata\_player
- Yaoqi ZHOU. Recipe for a quality Scientific Paper: Fulfill Readers' and Reviewers' Expectations. <u>http://sparks.informatics.uput.ed</u>
- EDANZ Editing training materials. 2006 <u>http://liwenbianji.com</u>, <u>http://www.edanzediting.com/english.html</u>
- Anthony Newman, Ethics White Paper <a href="http://www.ifcc.org/media/161822/IFCC%20Ethics%20in%20Science.pdf">http://www.ifcc.org/media/161822/IFCC%20Ethics%20in%20Science.pdf</a>
- 77

### **Questions?**



Or for questions later, please contact a.newman@elsevier.com

